FutureMeds Enters Turkey, Increasing Patient Access to Trials in the Country

FutureMeds has established a strategic partnership with HabCare CRO to strengthen patient access to clinical research in Turkey, combining FutureMeds @home capabilities with HabCare CRO’s local operational expertise.

As traditional European markets are becoming saturated, clinical development teams are looking eastward. Turkey has emerged as one of the most promising, yet underleveraged, destinations for clinical research. However, realising the full potential of this region requires a delicate balance of deep local expertise, sophisticated, modern operational infrastructure and the capability to go beyond traditional site catchment.

To bridge this gap, FutureMeds has entered into a strategic partnership with HabCare CRO. By combining FutureMeds’ pan-European @home decentralised clinical trial capabilities with HabCare’s established operational strength in Turkey, this partnership is designed to support Sponsors looking to include Turkey in clinical development programmes, particularly where patient access and retention are critical to study performance.

“For Sponsors and CROs, Turkey offers significant clinical research potential, but unlocking that potential requires strong local execution and patient-centred delivery. Our partnership with HabCare CRO brings together FutureMeds’ decentralised trial capabilities and HabCare’s operational expertise in Turkey to support more practical, accessible and reliable study delivery. This is an important step in building a long-term model that helps clients expand into high-potential markets without losing focus on quality, feasibility and the patient experience.”

— Iwona Tongbhoyai, Chief Growth Officer, FutureMeds

Why Turkey is Capturing the Attention of Global Sponsors

Turkey is rapidly becoming a core clinical trial destination. For sponsors managing complex protocols—particularly in oncology, rare diseases, central nervous system (CNS) disorders, and cardiovascular health—the country offers several distinct advantages:

A Vast, Diverse Patient Pool: With a population of over 85 million, Turkey provides access to large patient populations. High percentages of these patients are treatment-naive, which can dramatically accelerate recruitment timelines.

Advanced Healthcare System: The integrated nature of Turkey’s medical infrastructure allows for efficient identification and tracking of eligible trial participants across major medical centres.

High number of GCP-Trained Investigators: Turkish medical institutions boast highly experienced investigators who are deeply integrated into the global scientific community and routinely contribute to international trials.

While these factors make Turkey an incredibly attractive market, global sponsors have historically run into roadblocks when trying to navigate local regulatory nuances or implement decentralised trial elements.

Solving the Localisation and Decentralisation Puzzle

The true value of the FutureMeds and HabCare partnership lies in its ability to de-risk trial delivery while elevating the participant experience.

Traditional site-centric models often place a heavy burden on patients, leading to dropouts and risks to timelines. By introducing FutureMeds' @home to the Turkish market and research sites, the partnership enables sponsors to transition to hybrid and decentralised trial models.

“Our ambition has always been to bring clinical trials closer to the patient, regardless of geography. By introducing our @home decentralised capabilities into Turkey alongside HabCare, we are removing the physical barriers to participation. Utilising home nursing, localised remote monitoring, and home-based care makes participation safer and significantly easier for patients, which directly translates to higher retention rates and cleaner data for sponsors.”

— Gemma Whiteley, Managing Director, FutureMeds @home

What This Means for Sponsors: Core Advantages

For clinical operations leaders, this partnership translates into tangible, measurable benefits on the project dashboard:

Accelerated Time-to-Market: The combination of Turkey's motivated patient population, HabCare’s local expertise and @home’s rapid startup capabilities means fast startup timelines.

Reduced Vendor Fragmentation: Instead of managing separate site networks and local CROs across different borders, sponsors can leverage a cohesive operational framework that spans Europe and Turkey.

Enhanced Patient Retention: By deploying a tailored @home model, the partnership minimises the travel and administrative burdens that traditionally cause patient churn.

"We are thrilled to align our local expertise with FutureMeds’ international standards. This partnership doesn't just benefit global sponsors: it empowers our local investigators, sites and, most importantly, provides Turkish patients with unprecedented access to innovative, life-saving therapies right from their homes."

— Arife Şahin, Founder & General manager at Habcare

Looking Forward

As protocols demand more from sites and patient populations become harder to recruit, the success of global clinical trials will increasingly depend on strategic agility. The partnership between FutureMeds and HabCare CRO offers the clinical research industry exactly that: a high-performing gateway into a crucial research market, backed by the modern, patient-centric infrastructure required to deliver results.

To learn more about how this partnership can optimise your upcoming clinical programs and patient recruitment strategies in Europe and Turkey, contact our @home team at ed.snelling@futuremeds.com.

About HabCare

HabCare CRO is a nurse-led clinical research organisation in Turkey, founded by experienced clinical research professionals with more than 20 years of industry experience. The company provides nationwide on-site, off-site and home-visit clinical trial support, combining deep operational expertise with a strong understanding of patient and site needs.

Its services include research nursing, patient assessments, drug administration, sample collection and processing, logistics coordination, quality control and source documentation support. By working closely with investigators, sites, Sponsors and CROs, HabCare CRO helps deliver clinical trials more efficiently while reducing operational burden and improving the participant experience.

With nationwide reach, GCP-aligned processes and extensive experience supporting patient-facing trial activities, HabCare CRO enables high-quality study delivery across Turkey while helping bring research closer to patients.